Protagenic shares surge 12.12% premarket after positive Phase 1 safety results for PT00114, advancing to Phase 2 trials in stress-related disorders.

Protagenic Therapeutics (NASDAQ:PTIX) surged 12.12% in premarket trading following the release of positive Phase 1 multiple-dose study results for its experimental drug PT00114. The company reported that PT00114 was well tolerated in healthy volunteers, with no serious adverse events observed, and noted anecdotal reports of improved well-being. These findings support advancement to a Phase 2 trial in early 2026 for chronic stress-related psychiatric disorders. The safety data and pipeline progress align with the stock’s upward movement, as the results validate the drug’s potential to address an unmet medical need through a novel stress-axis modulating mechanism. Other news, including a Nasdaq non-compliance notice and technical issues on financial platforms, were either unrelated or secondary to the primary catalyst.